$38.42
−1.06%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$38.73
From 52W high−39.95%
Volume7.32M
Market cap$171.55B
P/E (TTM)9.8x
P/S (TTM)3.5x
Div yield3.89%
Key dataOct 19, 2026
Open
$38.73
From 52W high
−39.95%
Volume
7.32M
Market cap
$171.55B
ValuationView details →
P/E (Fwd)
11.5x
EV/EBITDA
6.8x
P/E (TTM)
9.8x
RSI (14)
40.2
MomentumView details →
1D Return
−1.06%
YTD Return
−24.46%
SummaryUpdated Jun 1, 2026
Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company founded in 1923 and headquartered in Bagsvaerd, Denmark. The company has evolved from its origins as an insulin manufacturer into a global leader in diabetes care and, more recently, obesity treatment. Novo Nordisk went public in 1981 and has grown to serve over 45 million patients worldwide with diabetes and obesity treatments. The company operates primarily through two business segments: Diabetes and Obesity Care, and Rare Disease, with the former representing the vast majority of its revenue and growth trajectory.
Similar companies
Latest newsMore news →
China’s National Medical Products Administration approved updated product information allowing NOVO NORDISK A S’s Wegovy semaglutide injection to be stored at 2°C–30°C for up to 48 hours before first opening during distribution to patients.13h agoChina’s National Medical Products Administration approved NOVO NORDISK A S’s application to add an indication for Awiqli (insulin icodec and semaglutide injection) for adults with type 2 diabetes inadequately controlled on oral glucose-lowering medicines.5d agoThe Center for Addiction Science, Policy and Research and the Allegheny County Department of Human Services plan to launch a trial testing Wegovy among adults with substance use disorders and high risk of criminal-justice involvement.5d ago